Nothing Special   »   [go: up one dir, main page]

BR112013018317A2 - mutantes de fc do anticorpo resistentes a protease ativa - Google Patents

mutantes de fc do anticorpo resistentes a protease ativa

Info

Publication number
BR112013018317A2
BR112013018317A2 BR112013018317A BR112013018317A BR112013018317A2 BR 112013018317 A2 BR112013018317 A2 BR 112013018317A2 BR 112013018317 A BR112013018317 A BR 112013018317A BR 112013018317 A BR112013018317 A BR 112013018317A BR 112013018317 A2 BR112013018317 A2 BR 112013018317A2
Authority
BR
Brazil
Prior art keywords
mutants
protease resistant
active protease
resistant antibody
antibody
Prior art date
Application number
BR112013018317A
Other languages
English (en)
Inventor
Brezski Randall
Jordan Robert
Strohl William
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112013018317A2 publication Critical patent/BR112013018317A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112013018317A 2010-12-23 2011-12-15 mutantes de fc do anticorpo resistentes a protease ativa BR112013018317A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061426619P 2010-12-23 2010-12-23
US201161540882P 2011-09-29 2011-09-29
PCT/US2011/065174 WO2012087746A1 (en) 2010-12-23 2011-12-15 Active protease-resistant antibody fc mutants

Publications (1)

Publication Number Publication Date
BR112013018317A2 true BR112013018317A2 (pt) 2017-03-21

Family

ID=46314374

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013018317A BR112013018317A2 (pt) 2010-12-23 2011-12-15 mutantes de fc do anticorpo resistentes a protease ativa

Country Status (32)

Country Link
US (2) US8871204B2 (pt)
EP (1) EP2654780B1 (pt)
JP (1) JP6012624B2 (pt)
KR (1) KR101900280B1 (pt)
CN (1) CN103260640B (pt)
AU (1) AU2011349719B2 (pt)
BR (1) BR112013018317A2 (pt)
CA (1) CA2822366A1 (pt)
CO (1) CO6741179A2 (pt)
CR (1) CR20130292A (pt)
CY (1) CY1118923T1 (pt)
DK (1) DK2654780T3 (pt)
EA (1) EA028658B1 (pt)
EC (1) ECSP13012712A (pt)
ES (1) ES2623912T3 (pt)
GT (1) GT201300167A (pt)
HR (1) HRP20170595T1 (pt)
HU (1) HUE033205T2 (pt)
IL (1) IL226987A (pt)
LT (1) LT2654780T (pt)
MX (1) MX347077B (pt)
MY (1) MY162489A (pt)
NI (1) NI201300057A (pt)
NZ (1) NZ612379A (pt)
PL (1) PL2654780T3 (pt)
PT (1) PT2654780T (pt)
RS (1) RS55906B1 (pt)
SG (1) SG191233A1 (pt)
SI (1) SI2654780T1 (pt)
SM (1) SMT201700201T1 (pt)
WO (1) WO2012087746A1 (pt)
ZA (1) ZA201305538B (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2618292T3 (es) 2008-01-31 2017-06-21 Inserm - Institut National De La Sante Et De La Recherche Medicale Anticuerpos contra CD39 humano y uso de los mismos para inhibir la actividad de las células T reguladoras
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
SG191233A1 (en) * 2010-12-23 2013-07-31 Janssen Biotech Inc Active protease-resistant antibody fc mutants
DK2726092T3 (da) 2011-06-28 2019-09-30 Inhibrx Lp Serpin-fusionspolypeptider og fremgangsmåder til anvendelse deraf
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
EP2812027A1 (en) 2012-02-07 2014-12-17 Innate Pharma Mica binding agents
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
ES2962694T3 (es) 2014-05-02 2024-03-20 Momenta Pharmaceuticals Inc Composiciones y procedimientos relacionados con construcciones de Fc manipuladas
DK3169703T4 (da) * 2014-07-16 2024-02-26 Hinrich Abken Kimær antigenreceptor og anvendelse deraf
CN104177496B (zh) * 2014-09-02 2015-03-11 安源生物科技(上海)有限公司 人IgG2抗体铰链区修饰体
WO2016055609A1 (en) 2014-10-10 2016-04-14 Innate Pharma Cd73 blockade
WO2016131950A1 (en) 2015-02-20 2016-08-25 Innate Pharma Cd73 blockade
IL251799B2 (en) * 2014-10-27 2024-04-01 Inhibrx Inc Serpin fusion polypeptides and methods of use thereof
WO2016081490A1 (en) 2014-11-17 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using cd3xcd20 bispecific antibody
US10196445B1 (en) 2015-03-17 2019-02-05 Bristol-Myers Squibb Company Ipilimumab variant with enhanced ADCC
US10556952B2 (en) 2015-03-30 2020-02-11 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to Fc gamma receptors
JP2018517708A (ja) 2015-06-05 2018-07-05 ニューヨーク・ユニバーシティ 抗ブドウ球菌生物学的薬剤のための組成物及び方法
AU2016297862C1 (en) 2015-07-24 2022-12-15 Gliknik Inc. Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin Fc compositions with enhanced complement binding
CN114605549A (zh) 2015-08-05 2022-06-10 詹森生物科技公司 抗cd154抗体及其使用方法
KR20180053738A (ko) 2015-09-30 2018-05-23 얀센 바이오테크 인코포레이티드 인간 cd40과 특이적으로 결합하는 길항적 항체 및 사용 방법
US11130817B2 (en) 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
WO2017068183A1 (en) * 2015-10-23 2017-04-27 Apogenix Ag Single-chain cd137-receptor agonist proteins
EP3912681A1 (en) 2016-03-14 2021-11-24 Orega Biotech Anti-cd39 antibodies
WO2017157895A1 (en) 2016-03-15 2017-09-21 Innate Pharma Anti-mica antibodies
BR112018074056A2 (pt) * 2016-05-23 2019-03-06 Momenta Pharmaceuticals, Inc. composições e métodos relacionados a construtos de fc manipulados
WO2017211321A1 (zh) * 2016-06-08 2017-12-14 上海交通大学医学院 增强激动型抗体活性的抗体重链恒定区序列
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
JP7308150B2 (ja) 2017-03-16 2023-07-13 イナート・ファルマ・ソシエテ・アノニム 癌を処置するための組成物及び方法
KR20200006526A (ko) * 2017-03-28 2020-01-20 리브젠 바이오파마 홀딩스 리미티드 종양 미세 환경에서 면역 반응을 향상시키기 위한 치료제 및 방법
BR112019023543A2 (pt) * 2017-05-10 2020-05-26 Albajuna Therapeutics, S.L. Derivados de proteína de fusão fc com alta atividade dual antiviral e imunomoduladora do hiv
LT3456736T (lt) 2017-09-19 2021-06-10 Tillotts Pharma Ag Antikūnų variantai
PT3807316T (pt) 2018-06-18 2024-07-29 Innate Pharma Composições e métodos para tratamento de cancro
MA53495A (fr) 2018-08-31 2021-12-08 Regeneron Pharma Stratégie de dosage permettant d'atténuer le syndrome de libération de cytokines pour des anticorps bispécifiques cd3/c20
EP3856764A4 (en) 2018-09-27 2022-11-02 Xilio Development, Inc. MASKED CYTOKINE POLYPEPTIDES
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
EP3711772A1 (en) 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Recombinant proteins and fusion proteins
JP2022524215A (ja) * 2019-03-28 2022-04-28 ダニスコ・ユーエス・インク 改変抗体
GB201906685D0 (en) 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
EP4017884A4 (en) * 2019-08-23 2024-01-17 City of Hope IGG ANTIBODY COMPOSITIONS AND METHODS OF MANUFACTURING THEREOF
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
CA3188426A1 (en) * 2020-08-07 2022-02-10 Yichin Liu Flt3 ligand fusion proteins and methods of use
WO2022167729A1 (en) * 2021-02-04 2022-08-11 Helsingin Yliopisto A cross-hybrid fc-fusion polypeptide targeting pd-l1 and methods and uses related thereto
CN117597365A (zh) * 2021-05-04 2024-02-23 再生元制药公司 多特异性fgf21受体激动剂及其应用
WO2023109928A1 (zh) 2021-12-16 2023-06-22 上海宝济药业有限公司 抗免疫球蛋白降解酶酶切的Fc变体
WO2024108137A2 (en) * 2022-11-18 2024-05-23 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
WO2024148276A1 (en) 2023-01-06 2024-07-11 Seismic Therapeutic, Inc. Protease variants and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69427974T2 (de) 1993-04-29 2001-12-06 Unilever N.V., Rotterdam Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
CA2331607A1 (en) 1998-05-06 1999-11-11 Temple University - Of The Commonwealth System Of Higher Education Reversal of proinflammatory response by ligating the macrophage fc.gamma.ri receptor
AU778683B2 (en) * 1999-01-15 2004-12-16 Genentech Inc. Polypeptide variants with altered effector function
CA2369292C (en) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
US7129331B2 (en) 2000-05-31 2006-10-31 Pestka Biomedical Laboratories, Inc. Phosphorylated polypeptides and uses related thereto
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
CA2592015A1 (en) 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
EP1937306B1 (en) 2005-08-19 2016-02-17 Janssen Biotech, Inc. Proteolysis resistant antibody preparations
AU2006299429B2 (en) * 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
EP2188306B1 (en) * 2007-08-10 2016-06-29 Janssen Biotech, Inc. Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
PH12021552811A1 (en) * 2007-09-26 2022-11-21 Chugai Seiyaku Kk Modified antibody constant region
DK2205258T3 (en) 2007-09-28 2017-08-28 Janssen Biotech Inc Method and structural conformations of antibody preparations with increased resistance to proteases
SI2211904T1 (sl) * 2007-10-19 2016-12-30 Seattle Genetics, Inc. CD19 vezavna sredstva in njihove uporabe
JP2012524545A (ja) 2009-04-21 2012-10-18 アムジェン インコーポレイテッド 断片化耐性ＩｇＧ１Ｆｃ−コンジュゲート
SG191233A1 (en) * 2010-12-23 2013-07-31 Janssen Biotech Inc Active protease-resistant antibody fc mutants
US8729985B2 (en) 2012-01-23 2014-05-20 Electro-Mechanical Corporation Switchgear visible disconnect mechanical interlock

Also Published As

Publication number Publication date
HUE033205T2 (en) 2017-11-28
US8871204B2 (en) 2014-10-28
LT2654780T (lt) 2017-03-27
EA028658B1 (ru) 2017-12-29
DK2654780T3 (en) 2017-04-10
CY1118923T1 (el) 2018-01-10
US9611328B2 (en) 2017-04-04
CR20130292A (es) 2013-10-03
ZA201305538B (en) 2015-01-28
KR101900280B1 (ko) 2018-11-08
JP2014504301A (ja) 2014-02-20
ECSP13012712A (es) 2013-08-30
US20150139984A1 (en) 2015-05-21
MY162489A (en) 2017-06-15
SI2654780T1 (sl) 2017-06-30
KR20140003485A (ko) 2014-01-09
AU2011349719B2 (en) 2016-09-15
PL2654780T3 (pl) 2017-07-31
HRP20170595T1 (hr) 2017-06-16
EP2654780A4 (en) 2015-03-18
SG191233A1 (en) 2013-07-31
WO2012087746A1 (en) 2012-06-28
PT2654780T (pt) 2017-04-06
CN103260640B (zh) 2015-12-02
JP6012624B2 (ja) 2016-10-25
MX2013007291A (es) 2013-09-13
NI201300057A (es) 2014-02-25
CO6741179A2 (es) 2013-08-30
AU2011349719A1 (en) 2013-07-04
EP2654780A1 (en) 2013-10-30
CA2822366A1 (en) 2012-06-28
NZ612379A (en) 2014-10-31
US20130011386A1 (en) 2013-01-10
EA201390958A1 (ru) 2013-11-29
CN103260640A (zh) 2013-08-21
SMT201700201T1 (it) 2017-05-08
RS55906B1 (sr) 2017-09-29
GT201300167A (es) 2014-09-26
IL226987A (en) 2017-07-31
ES2623912T3 (es) 2017-07-12
EP2654780B1 (en) 2017-02-01
MX347077B (es) 2017-04-10

Similar Documents

Publication Publication Date Title
BR112013018317A2 (pt) mutantes de fc do anticorpo resistentes a protease ativa
FR23C1023I2 (fr) Anticorps anti-il-36r
LTPA2019518I1 (lt) Antikūnai prieš IL-23
CY2019017I2 (el) Cgrp αντισωματα
HRP20181690T1 (hr) Varijante protutijela fc
BR112013033342A2 (pt) variantes de fc com funções atuadoras reduzidas
BR112012030311A2 (pt) anticorpo
EP2530091A4 (en) ANTI-DLL3 ANTIBODY
SG10201609665PA (en) FcɣRIIb-SPECIFIC Fc ANTIBODY
CO6811812A2 (es) Anticuerpo anti-b7-h3
CR20140127A (es) Anticuerpo anti-abtcr
CO6791565A2 (es) Anticuerpos anti-notch1
BR112013029769A2 (pt) levedura recombinante
BR112013023008A2 (pt) válvula de combustível.
BR112013019094A2 (pt) válvula de combustível anticapotamento
IT1401887B1 (it) Elettrovalvola.
EP2547598A4 (en) VALVE ARRANGEMENT
FR2973559B1 (fr) Pont de contact mobile
FI8750U1 (fi) Puhdistusväline
IT1398343B1 (it) Sezionatore a semi-pantografo.
IT1398919B1 (it) Bottone a pressione.
FR2959485B1 (fr) Ulm remorquable
FI20115176A0 (fi) Double click-teknologia

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]